Dorothy C. Y. Yiu, Brandon L. H. Chan, Alex C. F. Wong, Maple Y. Feng, Stephen L. Chan
{"title":"阿特珠单抗联合贝伐单抗治疗香港晚期肝细胞癌患者的实际经验","authors":"Dorothy C. Y. Yiu, Brandon L. H. Chan, Alex C. F. Wong, Maple Y. Feng, Stephen L. Chan","doi":"10.1002/lci2.76","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aims</h3>\n \n <p>The IMbrave150 trial established atezolizumab–bevacizumab as the new standard of care for hepatocellular carcinoma (HCC). However, evidence on its applications in real-world patients is limited. We report the efficacy and safety of atezolizumab–bevacizumab in a Chinese cohort of HCC patients ineligible for clinical trials.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Electronic medical records of patients diagnosed with HCC and with pharmacy orders of atezolizumab and bevacizumab between 2019 and 2021 were retrospectively reviewed. Patients' demographics, performance status, stage, treatment received, adverse events and death time (if any) were recorded.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Thirteen eligible patients were included. mOS of HCC patients was 18.6 months [6.8–30.4], while mPFS was 9.3 months [0–19.4]. No grade 5 adverse events were reported.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This real-world study provides real-world experiences of atezolizumab–bevacizumab as first-line and subsequent therapy in patients with unresectable HCC. Further validation on the efficacy and safety of atezolizumab–bevacizumab as second-line or later lines of treatment should be conducted.</p>\n </section>\n </div>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"4 3-4","pages":"121-126"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.76","citationCount":"0","resultStr":"{\"title\":\"Real-world experiences of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma in Hong Kong\",\"authors\":\"Dorothy C. Y. Yiu, Brandon L. H. Chan, Alex C. F. Wong, Maple Y. Feng, Stephen L. Chan\",\"doi\":\"10.1002/lci2.76\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and Aims</h3>\\n \\n <p>The IMbrave150 trial established atezolizumab–bevacizumab as the new standard of care for hepatocellular carcinoma (HCC). However, evidence on its applications in real-world patients is limited. We report the efficacy and safety of atezolizumab–bevacizumab in a Chinese cohort of HCC patients ineligible for clinical trials.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Electronic medical records of patients diagnosed with HCC and with pharmacy orders of atezolizumab and bevacizumab between 2019 and 2021 were retrospectively reviewed. Patients' demographics, performance status, stage, treatment received, adverse events and death time (if any) were recorded.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Thirteen eligible patients were included. mOS of HCC patients was 18.6 months [6.8–30.4], while mPFS was 9.3 months [0–19.4]. No grade 5 adverse events were reported.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>This real-world study provides real-world experiences of atezolizumab–bevacizumab as first-line and subsequent therapy in patients with unresectable HCC. Further validation on the efficacy and safety of atezolizumab–bevacizumab as second-line or later lines of treatment should be conducted.</p>\\n </section>\\n </div>\",\"PeriodicalId\":93331,\"journal\":{\"name\":\"Liver cancer international\",\"volume\":\"4 3-4\",\"pages\":\"121-126\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.76\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver cancer international\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/lci2.76\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver cancer international","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/lci2.76","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Real-world experiences of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma in Hong Kong
Background and Aims
The IMbrave150 trial established atezolizumab–bevacizumab as the new standard of care for hepatocellular carcinoma (HCC). However, evidence on its applications in real-world patients is limited. We report the efficacy and safety of atezolizumab–bevacizumab in a Chinese cohort of HCC patients ineligible for clinical trials.
Methods
Electronic medical records of patients diagnosed with HCC and with pharmacy orders of atezolizumab and bevacizumab between 2019 and 2021 were retrospectively reviewed. Patients' demographics, performance status, stage, treatment received, adverse events and death time (if any) were recorded.
Results
Thirteen eligible patients were included. mOS of HCC patients was 18.6 months [6.8–30.4], while mPFS was 9.3 months [0–19.4]. No grade 5 adverse events were reported.
Conclusions
This real-world study provides real-world experiences of atezolizumab–bevacizumab as first-line and subsequent therapy in patients with unresectable HCC. Further validation on the efficacy and safety of atezolizumab–bevacizumab as second-line or later lines of treatment should be conducted.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
